Alkermes plc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Large accelerated filer
Business Address
CONNAUGHT HOUSE, DUBLIN 4, L2, 00000
Mailing Address
CONNAUGHT HOUSE, DUBLIN 4, L2, 00000
Phone
00-353-1-772-8000
Fiscal Year End
1231
EIN
981007018
Financial Overview
FY2025
$367.07M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 6, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | April 6, 2026 | View on SEC |
| 4 Insider stock transaction report | April 1, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
Material Events
8-K
Leadership Change
February 25, 2026
High Impact
- Smooth, planned CEO succession from long-serving Richard F. Pops to internal COO Blair C. Jackson.
- Outgoing CEO Pops remains involved as Senior Advisor and non-executive Chairman, ensuring continuity and stability.
Insider Trading
STRONG SELL
5 insiders
13 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.